Established this past summer season at the i-Lab, Confi works as an online platform that crowdsources advice on sexual health targeted at ladies and operates in tandem with medical professionals to drop light on topics some might consider too taboo to ask about.
“Our goal when creating Confi is that there was truly no one resource for individuals when they have questions about sexual health,” said Kristen Y. Shim ’17, a member of Confi’s four-woman team. People normally go to online forums for information, which’s not reliable details, and it’s often very sexist.”
According to Confi CEO and Harvard Company School student Tess D. Brooks, studies carried out by the company have actually revealed that females typically feel uncomfortable buying sexual health products at drug stores or at online vendors like Amazon. In response, Confi prepares to sell womanly sexual health “starter kits,” including a variety of condoms, lubricants, and pregnancy tests. Shim stated Confi will test this profit-generating model in the spring.
For Confi, enhancing the number of online users, having actually seen its web traffic increase by 60 percent over the previous quarter, and finding sources of revenue are top concerns, Brooks said. While Confi will soon test the viability of offering womanly health products as an approach of producing earnings, Confi might likewise start to approach business sponsors.
Another team, Antera, founded in December 2014, is planning to become the leading expert in vaccination versus food and ecological allergens. The business concentratesconcentrates on lowering the occurrance of peanut allergies, which have increased threefold in the United States since 2004, according to founder and CEO Clarence D. Friedman. The start-up is “disrupting the design of healthcare,” by targeting allergen tolerance from a preventative viewpoint, added Friedman, a 2015 Company School graduate.Antera’s existing
item, Aralyte, is a focused dose of peanut protein givenoffered to children from early stage to expose them to the prospective irritant. While special, this approach to allergies is supported by contemporary research in the field, according to Friedman. He included that a February 2015 research on early prevention of peanut allergies conducted by the Immune Tolerance Network supported the company’s claims.
“In the future we’ll expand to the other irritants that account for 95 percent of food allergies such as tree nuts, shellfish, soy, and wheat,” Friedman said, including that the company will continue beta-testing Aralyte for another 4 months. “We ‘d actually want to go to ecological allergies too. We really desirewish to become the company that vaccinates versus all allergies.”
Beginning allergies from this viewpoint features its own set of obstacles, stated Friedman and Caroline L. Sokol, a teacher at Harvard Medical School and a member of Antera’s clinical advisory board.
Because of the potential for an adverse reaction to the peanut protein, a doctor administers the first dose, while parents provide the subsequent dosages. According to Sokol, this process will require some screening.
“It is not a common technique of providing medication,” she stated. “You have moms and dads out there who, if there has actually been a family history of peanut allergies, are anxious about giving that very first dose of a possible allergen to their children.”
Friedman indicated having access to resources and a network of business owners through the i-Lab as pivotal to his business’s success.
“It’s a great little circle where everyone is helping each other out, and it’s been an incubator in the finest sense of the word,” Friedman stated. “We have grown exceptionally rapidly due to the individuals around.”
— Staff writer Ignacio Sabate can be reached at firstname.lastname@example.org. Follow him on Twitter @ignacio_sabate.…